JONGWON LIM
Broker in Lexington, MA
License number
Massachusetts 9532854
Issued Date
Jul 26, 2014
Expiration Date
Mar 27, 2017
Type
Salesperson
Address
Address
Lexington, MA 02420
Professional information
Pyrazolo[1,5-A]Pyrimidines As Mark Inhibitors
US Patent:
2013021, Aug 15, 2013
Filed:
Jan 11, 2011
Appl. No.:
13/521382
Inventors:
Jongwon Lim - Lexington MA, US
Brandon M. Taoka - Hoboken NJ, US
Sandra Lee - Princeton NJ, US
Alan Northrup - Reading MA, US
Michael D. Altman - Needham MA, US
David L. Sloman - Boston MA, US
Matthew G. Stanton - Marlton NJ, US
Brandon M. Taoka - Hoboken NJ, US
Sandra Lee - Princeton NJ, US
Alan Northrup - Reading MA, US
Michael D. Altman - Needham MA, US
David L. Sloman - Boston MA, US
Matthew G. Stanton - Marlton NJ, US
International Classification:
C07D 487/04
US Classification:
5142593, 544281
Abstract:
The invention encompasses pyrazolo[1,5-a]pyrimidine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
Inhibitors Of Janus Kinases
US Patent:
8367706, Feb 5, 2013
Filed:
Jun 16, 2008
Appl. No.:
12/665045
Inventors:
Michael Altman - Cambridge MA, US
Matthew Christopher - Wallingford CT, US
Jonathan B. Grimm - Newton MA, US
Andrew Haidle - Cambridge MA, US
Kaleen Konrad - Newton MA, US
Jongwon Lim - Lexington MA, US
Rachel N. MacCoss - Brookline MA, US
Michelle Machacek - Brookline MA, US
Ekundayo Osimboni - Ashland MA, US
Ryan D. Otte - Natick MA, US
Tony Siu - Brookline MA, US
Kerrie Spencer - Woonsocket RI, US
Brandon Taoka - Allston MA, US
Paul Tempest - Brookline MA, US
Kevin Wilson - West Newton MA, US
Hyun Chong Woo - Brookline MA, US
Jonathan Young - Southborough MA, US
Anna Zabierek - Salem MA, US
Matthew Christopher - Wallingford CT, US
Jonathan B. Grimm - Newton MA, US
Andrew Haidle - Cambridge MA, US
Kaleen Konrad - Newton MA, US
Jongwon Lim - Lexington MA, US
Rachel N. MacCoss - Brookline MA, US
Michelle Machacek - Brookline MA, US
Ekundayo Osimboni - Ashland MA, US
Ryan D. Otte - Natick MA, US
Tony Siu - Brookline MA, US
Kerrie Spencer - Woonsocket RI, US
Brandon Taoka - Allston MA, US
Paul Tempest - Brookline MA, US
Kevin Wilson - West Newton MA, US
Hyun Chong Woo - Brookline MA, US
Jonathan Young - Southborough MA, US
Anna Zabierek - Salem MA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/4436, C07D 409/12
US Classification:
514336, 5462814
Abstract:
The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
Tyrosine Kinase Inhibitors
US Patent:
2009013, May 21, 2009
Filed:
Oct 18, 2006
Appl. No.:
12/083746
Inventors:
Christopher J. Dinsmore - Newton MA, US
Ana Esther Gabarda Ortega - Madrid, ES
Jongwon Lim - Lexington MA, US
Michelle R. Machacek - Boston MA, US
Alan B. Northrup - Reading MA, US
Jonathan R. Young - Southborough MA, US
Ana Esther Gabarda Ortega - Madrid, ES
Jongwon Lim - Lexington MA, US
Michelle R. Machacek - Boston MA, US
Alan B. Northrup - Reading MA, US
Jonathan R. Young - Southborough MA, US
Assignee:
MERCK & CO., INC. - Rahway NJ
International Classification:
A61K 31/5377, C07D 471/04, A61K 31/4375, A61K 31/496, A61P 35/00, C07D 401/14, C07D 413/14
US Classification:
5142328, 546 81, 514292, 544126, 544361, 51425303
Abstract:
The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Tyrosine Kinase Inhibitors
US Patent:
7790739, Sep 7, 2010
Filed:
Oct 18, 2006
Appl. No.:
12/083745
Inventors:
Jongwon Lim - Lexington MA, US
Ana Esther Gabarda Ortega - Madrid, ES
Ana Esther Gabarda Ortega - Madrid, ES
Assignee:
Merck & Co., Inc. and Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/44, C07D 455/04, C07D 413/00
US Classification:
514290, 546 80, 548126
Abstract:
The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Pyridin-4-Ylamine Compounds Useful In The Treatment Of Neuropathic Pain
US Patent:
2007009, May 3, 2007
Filed:
Nov 18, 2004
Appl. No.:
10/580393
Inventors:
Jongwon Lim - Lexington MA, US
Julia Boueres - Pomezia, IT
Benito Munoz - Brookline MA, US
Richard Pracitto - North Wales PA, US
Nicholas Stock - San Diego CA, US
Shankar Venkatraman - Lansdale PA, US
Julia Boueres - Pomezia, IT
Benito Munoz - Brookline MA, US
Richard Pracitto - North Wales PA, US
Nicholas Stock - San Diego CA, US
Shankar Venkatraman - Lansdale PA, US
International Classification:
A61K 31/473, C07D 219/12
US Classification:
514297000, 546106000
Abstract:
The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders—such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to αδ-1 subunit of Ca channels.
Benzocycloheptapyridines As Inhibitors Of The Receptor Tyrosine Kinase Met
US Patent:
2009019, Aug 6, 2009
Filed:
Jun 22, 2006
Appl. No.:
11/921350
Inventors:
Christopher J. Dinsmore - Newton MA, US
Ana Esther Gabarda Ortega - Madrid, ES
David J. Guerin - Natick MA, US
James P. Jewell - Sandwich MA, US
Jason D. Katz - Newton Highlands MA, US
Jongwon Lim - Lexington MA, US
Michelle R. Machacek - Boston MA, US
Ryan D. Otte - Newton Centre MA, US
Jonathan R. Young - Southborough MA, US
Ana Esther Gabarda Ortega - Madrid, ES
David J. Guerin - Natick MA, US
James P. Jewell - Sandwich MA, US
Jason D. Katz - Newton Highlands MA, US
Jongwon Lim - Lexington MA, US
Michelle R. Machacek - Boston MA, US
Ryan D. Otte - Newton Centre MA, US
Jonathan R. Young - Southborough MA, US
International Classification:
A61K 31/4353, C07D 221/06, A61P 35/00
US Classification:
514290, 546 93
Abstract:
The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Tyrosine Kinase Inhibitors
US Patent:
2006029, Dec 28, 2006
Filed:
Jun 22, 2006
Appl. No.:
11/473273
Inventors:
Christopher Dinsmore - Newton MA, US
Ana Gabarda Ortega - Madrid, ES
David Guerin - Natick MA, US
James Jewell - Sandwich MA, US
Jason Katz - Newton Highlands MA, US
Jongwon Lim - Lexington MA, US
Michelle Machacek - Boston MA, US
Ryan Otte - Newton Centre MA, US
Jonathan Young - Southborough MA, US
Ana Gabarda Ortega - Madrid, ES
David Guerin - Natick MA, US
James Jewell - Sandwich MA, US
Jason Katz - Newton Highlands MA, US
Jongwon Lim - Lexington MA, US
Michelle Machacek - Boston MA, US
Ryan Otte - Newton Centre MA, US
Jonathan Young - Southborough MA, US
International Classification:
A61K 31/473, C07D 221/02
US Classification:
514290000, 546093000
Abstract:
The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Tyrosine Kinase Inhibitors
US Patent:
2009029, Nov 26, 2009
Filed:
Oct 18, 2006
Appl. No.:
12/083818
Inventors:
Christopher J. Dinsmore - Newton MA, US
Jongwon Lim - Lexington MA, US
Alan B. Northrup - Reading MA, US
Jongwon Lim - Lexington MA, US
Alan B. Northrup - Reading MA, US
International Classification:
A61K 31/55, A61K 31/4375, C07D 487/14, C07D 471/00
US Classification:
51421206, 514292, 540461, 540521, 546 81
Abstract:
The present invention relates to pyrido[3,2-c]benzazocinone derivatives and related compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
Imidazo[1,2-A]Pyridines And Imidazo[1,2-B]Pyridazines As Mark Inhibitors
US Patent:
8592425, Nov 26, 2013
Filed:
Jan 12, 2010
Appl. No.:
13/144123
Inventors:
Michael D. Altman - Needham MA, US
Mark T. Bilodeau - Lansdale PA, US
Jongwon Lim - Lexington MA, US
Alan Northrup - Reading MA, US
Matthew G. Stanton - Holland PA, US
Brandon M. Taoka - Allston MA, US
Mark T. Bilodeau - Lansdale PA, US
Jongwon Lim - Lexington MA, US
Alan Northrup - Reading MA, US
Matthew G. Stanton - Holland PA, US
Brandon M. Taoka - Allston MA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A01N 43/58, A61K 31/50, C07D 487/00
US Classification:
514250, 544236
Abstract:
The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
Pyrazolo[1,5-A]Pyrimidine Derivatives
US Patent:
8461162, Jun 11, 2013
Filed:
Jul 16, 2008
Appl. No.:
12/669843
Inventors:
Matthew G. Stanton - Medfield MA, US
David L. Sloman - Boston MA, US
Jongwon Lim - Lexington MA, US
Benito Munoz - Newton MA, US
David L. Sloman - Boston MA, US
Jongwon Lim - Lexington MA, US
Benito Munoz - Newton MA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A01N 43/90, A61K 31/519, C07D 487/00
US Classification:
5142593, 544281
Abstract:
Compounds of the following formula (I) are inhibitors of microtubule affinity regulating kinase, and hence find use in the treatment of neurodegenerative diseases associated with hyperphosphorylation of tau.